Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells

Autor(es):Mostrar menos -

Andrade, F. O. ^[1] ; Nagamine, M. K. ^[2] ; De Conti, A. ^[1] ; Chaible, L. M. ^[2] ; Fontelles, C. C. ^[1] ; Jordao Junior, A. A. ^[3] ; Vannucchi, H. ^[3] ; Dagli, M. L. Z. ^[2] ; Bassoli, B. K. ^[1] ; Moreno, F. S. ^[1] ; Ong, T. P. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Alimentos & Nutr Expt, Lab Dieta Nutr & Canc, BR-05508900 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Patol, Expt Oncol Lab, BR-05508900 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Nutr, Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 45, n. 9, p. 841-850, SEP 2012.
• Citações Web of Science: 4

Resumo

The combined treatment with histone deacetylase inhibitors (HDACi) and retinoids has been suggested as a potential epigenetic strategy for the control of cancer. In the present study, we investigated the effects of treatment with butyrate, a dietary HDACi, combined with vitamin A on MCF-7 human breast cancer cells. Cell proliferation was evaluated by the crystal violet staining method. MCF-7 cells were plated at 5 x 10(4) cells/mL and treated with butyrate (1 mM) alone or combined with vitamin A (10 mu M) for 24 to 120 h. Cell proliferation inhibition was 34, 10 and 46% following treatment with butyrate, vitamin A and their combination, respectively, suggesting that vitamin A potentiated the inhibitory activities of butyrate. Furthermore, exposure to this short-chain fatty acid increased the level of histone H3K9 acetylation by 9.5-fold (Western blot), but not of H4K16, and increased the expression levels of p21(WAF1) by 2.7-fold (Western blot) and of RAR beta by 2.0-fold (quantitative real-time PCR). Our data show that RAR beta may represent a molecular target for butyrate in breast cancer cells. Due to its effectiveness as a dietary HDACi, butyrate should be considered for use in combinatorial strategies with more active retinoids, especially in breast cancers in which RAR beta is epigenetically altered. (AU)

• Processo FAPESP: 08/51742-9 - Alvos epigenéticos da associação entre ácido butírico e vitamina A no câncer de mama
• Beneficiário: Fábia de Oliveira Andrade
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 08/58697-9 - Alvos epigeneticos da associacao entre tributirina e vitamina a no cancer de mama
• Beneficiário: Thomas Prates Ong
• Modalidade de apoio: Auxílio à Pesquisa - Regular